Monitoring fertility using a new device that tracks cervical mucus changes
Detection of Fertile Window and Ovulation with At-Home Kegg Fertility Monitor: a Comparative Study with Standardized Cervical Mucus Observations and Urine Hormone Measurements
Lady Technologies Inc · NCT06862440
This study tests a new device that tracks changes in cervical mucus to help people better understand their fertility and identify their most fertile days.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | Female |
| Sponsor | Lady Technologies Inc (industry) |
| Locations | 1 site (San Francisco, California) |
| Trial ID | NCT06862440 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of the Kegg device, which measures electrical impedance in cervical mucus to provide real-time fertility status. Traditional methods like calendar tracking and basal body temperature monitoring have limitations in accurately identifying the fertile window. The Kegg device aims to improve fertility awareness by offering a more precise and convenient way to track ovulation. Participants will be trained in cervical mucus observation and will use the device daily to gather data on their fertility status.
Who should consider this trial
Good fit: Ideal candidates are biological females aged 18-40 who are actively trying to conceive and can use the Kegg device.
Not a fit: Patients who are postmenopausal, have had a hysterectomy, or are currently pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance fertility awareness and improve the chances of conception for women trying to conceive.
How similar studies have performed: Previous studies have shown that similar approaches to monitoring fertility can be effective, suggesting potential success for this novel method.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Biological female 2. Age between 18-40 years old 3. Participant has provided signed informed consent 4. Completed cervical mucus observation training 5. Owns and uses daily a smart device meeting the following requirement: Apple iPad or iPhone running iOS 13 or newer, or Apple Watch running WatchOS 6.0 or newer, or Android operating system of 6.0 or newer 6. Has readily accessible internet 7. Legal residents of the continental United States, excluding Alaska and Hawaii. Exclusion Criteria: 1. Participant is unable to read and understand English 2. Postmenopausal women 3. Women with hysterectomy 4. Pregnancy 5. Hormonal or intrauterine contraceptives or other hormone use prior to start of study enrollment \[No oral hormonal contraceptives or other hormones for at least one month, no implantable contraceptives or hormonal or non-hormonal intrauterine device for at least two months (\~2 cycles), no injectable hormonal contraceptives or other hormones in past 9 months from the most recent injection and resumption of regular menstrual cycles
Where this trial is running
San Francisco, California
- Lady Technologies Inc — San Francisco, California, United States (RECRUITING)
Study contacts
- Study coordinator: The Kegg Fertility Study Team
- Email: clinicalresearch@kegg.tech
- Phone: 628-500-9161
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Fertility